Daraxonrasib (RMC-6236), the first orally bioavailable pan-RAS(ON) inhibitor to reach clinical success, reduced the risk of death by 60% versus chemotherapy in the Phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma (hazard ratio 0.40; p < 0.0001). A new review in Cardio-Oncology examines what cardiovascular harm has actually been documented for this agent, and the answer is narrower than the biology might suggest: two reproducible vascular signals, and no published cardiac-specific endpoint data at Phase 3 scale.
The drug works through high-affinity engagement of GTP-loaded KRAS, NRAS and HRAS via a cyclophilin A-mediated tri-complex. That mechanism cannot distinguish oncogenic RAS in its active, GTP-bound state from the wild-type RAS(ON) that is constitutively active in cardiomyocytes, endothelial cells and vascular smooth muscle. This overlap is the theoretical basis for concern about cardiovascular toxicity, and the review’s authors set out to separate documented clinical observations from mechanistic inference.
Three cardiovascular observations are reproducible in exposed patients. Peripheral oedema occurs in approximately 40% of treated patients, treatment-emergent hypertension appears in a minority, and no left ventricular ejection fraction, strain, troponin or electrocardiographic data have been published at Phase 3 scale. In other words, the clinical picture so far is vascular rather than myocardial, and the myocardial consequences of pan-RAS(ON) inhibition remain inferential.
Post-marketing surveillance adds little clarity so far. The authors searched the FDA Adverse Event Reporting System, EudraVigilance and WHO VigiBase, together with PubMed, EMBASE, ClinicalTrials.gov, the Cochrane Library and major congress proceedings through 31 May 2026. No disproportionality signal could be computed in any of the three pharmacovigilance databases, because marketing exposure is too recent to have generated an analysable case series. The review stresses that this data immaturity should not be read as demonstrated safety.
To interpret the observations mechanistically, the review maps how wild-type RAS(ON) signalling sustains cardiomyocyte survival, endothelial function and vascular homeostasis through the RAF–MEK–ERK, PI3K–AKT–mTOR and RALGDS–RAC1 effector pathways. From this map, three liabilities follow. Endothelial dysfunction through reduced eNOS activation is graded Probable. Paradoxical ERK activation in wild-type-RAS vascular smooth muscle, promoting hypertension, is also graded Probable. Impaired reperfusion injury salvage kinase signalling at reperfusion is graded Possible, downgraded from Probable in the review’s revision.
One potential counterbalancing benefit is noted: reduced oxidative stress through NOX2 suppression, graded Possible. The authors also draw on RASopathy genotype–phenotype associations, which they describe as the human genetic validation for RAS–cardiac coupling. Claims relating to ischaemic conditioning are handled conservatively, because randomised trials of ischaemic pre-, post- and remote conditioning have been largely neutral, and routine peri-infarct pharmacotherapy already recruits the same pro-survival kinases.
Methodologically, the review assigns each claim an evidence tier and a strength grade of Established, Probable, Possible or Speculative, applied consistently throughout. This grading matters for readers, because it keeps the distinction visible between what has been measured in patients and what follows from pathway biology. The hypertension signal, for example, is both clinically observed and mechanistically supported, whereas any effect on myocardial salvage at reperfusion rests on inference alone.
The review’s practical conclusion is that the two reproducible clinical signals are vascular, and because no cardiac endpoint has been collected, the priority now is protocol-mandated cardiovascular measurement embedded in the trials that are already running, rather than further mechanistic argument. Such measurement would for the first time allow LVEF, strain, troponin and electrocardiographic changes under pan-RAS(ON) inhibition to be characterised prospectively.
For clinicians and researchers following the pan-RAS inhibitor class, the review frames the current state of knowledge plainly: the cardiovascular effects of daraxonrasib are biologically plausible and, in the vasculature, already partly visible, while myocardial consequences remain unmeasured. As daraxonrasib moves toward broader use following its survival benefit in metastatic pancreatic ductal adenocarcinoma, the absence of cardiac endpoint data is itself the finding that defines the surveillance agenda.
Subject of Research: Cardiovascular effects of the pan-RAS(ON) inhibitor daraxonrasib
Article Title: Daraxonrasib and the heart: cardiovascular implications of the first clinically successful pan-RAS(ON) inhibitor
Article References: Hullon, D., Ahad, A., Singh, T., Rekhraj, A. S., & Monga, P. (2026). Daraxonrasib and the heart: cardiovascular implications of the first clinically successful pan-RAS(ON) inhibitor. Cardio-Oncology. https://doi.org/10.1186/s40959-026-00579-8
Image Credits: AI Generated
DOI: 10.1186/s40959-026-00579-8
Keywords: daraxonrasib, pan-RAS(ON) inhibitor, cardio-oncology, RASolute 302, hypertension, peripheral oedema, RAS signalling, pharmacovigilance, pancreatic ductal adenocarcinoma, cardiac surveillance, heart, cardiovascular
News Source: Nathaniel Bowman. (October 30, 2026). First pan-RAS inhibitor shows vascular signals but no cardiac endpoint data yet. Scienmag.
